Business Description
Arrowhead Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US04280A1007
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.86 | |||||
Equity-to-Asset | 0.26 | |||||
Debt-to-Equity | 0.74 | |||||
Debt-to-EBITDA | -0.44 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 0.18 | |||||
Beneish M-Score | -4.9 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 37.2 | |||||
3-Year EBITDA Growth Rate | -23.9 | |||||
3-Year EPS without NRI Growth Rate | -31.7 | |||||
3-Year FCF Growth Rate | -42.5 | |||||
3-Year Book Growth Rate | -17.5 | |||||
Future 3-5Y Total Revenue Growth Rate | 5.18 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 30.8 | |||||
9-Day RSI | 30.89 | |||||
14-Day RSI | 32.55 | |||||
6-1 Month Momentum % | 14.1 | |||||
12-1 Month Momentum % | -21.62 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.73 | |||||
Quick Ratio | 3.73 | |||||
Cash Ratio | 3.46 | |||||
Days Sales Outstanding | 56.06 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.6 | |||||
Shareholder Yield % | -1.18 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -164.75 | |||||
Net Margin % | -163.32 | |||||
FCF Margin % | -221.58 | |||||
ROE % | -91.59 | |||||
ROA % | -37.38 | |||||
ROIC % | -81.36 | |||||
ROC (Joel Greenblatt) % | -100.15 | |||||
ROCE % | -40.11 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 13.14 | |||||
PB Ratio | 14.83 | |||||
Price-to-Tangible-Book | 15.79 | |||||
EV-to-EBIT | -9.34 | |||||
EV-to-Forward-EBIT | -6.64 | |||||
EV-to-EBITDA | -9.83 | |||||
EV-to-Forward-EBITDA | -6.19 | |||||
EV-to-Revenue | 14.52 | |||||
EV-to-Forward-Revenue | 34.68 | |||||
EV-to-FCF | -6.55 | |||||
Price-to-Median-PS-Value | 0.34 | |||||
Earnings Yield (Greenblatt) % | -10.71 | |||||
FCF Yield % | -14.69 |